Compare TELA & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TELA | LSTA |
|---|---|---|
| Founded | 2012 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 28.9M |
| IPO Year | 2019 | 2000 |
| Metric | TELA | LSTA |
|---|---|---|
| Price | $1.25 | $1.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $2.08 | N/A |
| AVG Volume (30 Days) | 236.8K | ★ 265.5K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.59 | 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $80,275,000.00 | $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.84 | ★ 56.90 |
| 52 Week Low | $0.50 | $0.99 |
| 52 Week High | $1.60 | $5.07 |
| Indicator | TELA | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 43.03 |
| Support Level | $0.61 | $1.35 |
| Resistance Level | $1.22 | $2.06 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 44.17 | 1.72 |
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.